📣 VC round data is live. Check it out!

C4 Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for C4 Therapeutics and similar public comparables like Prothena Corp., Kyverna Therapeutics, 4D Molecular Therapeutics, Assembly Biosciences and more.

C4 Therapeutics Overview

About C4 Therapeutics

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.


Founded

2015

HQ

United States

Employees

110

Financials (LTM)

Revenue: $30M
Net Income: ($112M)

EV

$305M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

C4 Therapeutics Financials

C4 Therapeutics reported last 12-month revenue of $30M.

In the same LTM period, C4 Therapeutics generated $27M in gross profit and had net loss of ($112M).

Revenue (LTM)


C4 Therapeutics P&L

In the most recent fiscal year, C4 Therapeutics reported revenue of $36M and EBITDA of ($103M).

C4 Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (285%) and net margin of (292%).

See analyst estimates for C4 Therapeutics
LTMLast FY202320242025202620272028
Revenue$30M$36M$21M$36M$36M
Gross Profit$27M---$30M
Gross Margin90%---85%
EBITDA-($103M)($128M)($103M)($103M)
EBITDA Margin-(285%)(616%)(290%)(285%)
EBIT Margin(406%)(291%)(670%)(329%)(291%)
Net Profit($112M)($105M)($132M)($105M)($105M)
Net Margin(368%)(292%)(638%)(296%)(292%)

Financial data powered by Morningstar, Inc.

C4 Therapeutics Stock Performance

C4 Therapeutics has current market cap of $482M, and enterprise value of $305M.

Market Cap Evolution


C4 Therapeutics' stock price is $4.36.

C4 Therapeutics share price decreased by 0.2% in the last 30 days, and increased by 204.9% in the last year.

C4 Therapeutics has an EPS (earnings per share) of $-0.95.

See more trading valuation data for C4 Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$305M$482M-0.5%-0.2%65.8%204.9%$-0.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

C4 Therapeutics Valuation Multiples

C4 Therapeutics trades at 10.0x EV/Revenue multiple, and (3.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for C4 Therapeutics

EV / Revenue (LTM)


C4 Therapeutics Financial Valuation Multiples

As of June 3, 2026, C4 Therapeutics has market cap of $482M and EV of $305M.

C4 Therapeutics has a P/E ratio of (4.3x).

LTMLast FY202320242025202620272028
EV/Revenue10.0x8.5x14.7x8.6x8.5x
EV/EBITDA-(3.0x)(2.4x)(2.9x)(3.0x)
EV/EBIT(2.5x)(2.9x)(2.2x)(2.6x)(2.9x)
EV/Gross Profit11.2x---10.0x
P/E(4.3x)(4.6x)(3.6x)(4.6x)(4.6x)
EV/FCF-(3.1x)(2.8x)(4.7x)(3.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified C4 Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

C4 Therapeutics Margins & Growth Rates

C4 Therapeutics decreased revenue by 36% but net profit grew by 16% in the last fiscal year.

In the most recent fiscal year, C4 Therapeutics reported EBITDA margin of (285%) and net margin of (292%).

See estimated margins and future growth rates for C4 Therapeutics

C4 Therapeutics Margins

Last FY202420252026202720282029
Gross Margin--85%100%
EBITDA Margin(285%)(290%)(285%)-
EBIT Margin(291%)(329%)(291%)(592%)
Net Margin(292%)(296%)(292%)(532%)
FCF Margin(276%)(184%)(276%)-

C4 Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(36%)71%1%(36%)
Gross Profit Growth---(25%)
EBITDA Growth-(19%)(1%)-
EBIT Growth29%(16%)(11%)29%
Net Profit Growth16%(21%)(0%)16%
FCF Growth-(40%)52%-

Data powered by FactSet, Inc. and Morningstar, Inc.

C4 Therapeutics Operational KPIs

C4 Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.3M for the same period.

Access forward-looking KPIs for C4 Therapeutics
LTMLast FY202320242025202620272028
Revenue per Employee-$0.3M---
Opex per Employee-$1.3M---
G&A Expenses to Revenue129%101%203%118%101%
R&D Expenses to Revenue358%290%567%311%290%
Opex to Revenue-391%770%429%391%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

C4 Therapeutics Competitors

C4 Therapeutics competitors include Prothena Corp., Kyverna Therapeutics, 4D Molecular Therapeutics, Assembly Biosciences, YungShin Global Holding, Synmosa Biopharma, Blau FarmacĂȘutica, CytoDyn, PKU Healthcare and Medigen Vaccine Biologics.

Most C4 Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Prothena Corp.16.4x3.9x(0.9x)-
Kyverna Therapeutics--(1.7x)(1.6x)
4D Molecular Therapeutics1.3x2.1x(0.8x)(0.5x)
Assembly Biosciences3.6x3.9x(21.8x)47.7x
YungShin Global Holding1.6x-8.5x-
Synmosa Biopharma2.4x-12.3x-
Blau FarmacĂȘutica1.5x1.4x4.7x5.6x
CytoDyn----

This data is available for Pro users. Sign up to see all C4 Therapeutics competitors and their valuation data.

Start Free Trial

C4 Therapeutics VC Funding History

Before going public, C4 Therapeutics raised $73M in total equity funding, across 1 round.


C4 Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-16Series ACobro Ventures; Cormorant Asset Management; EG Capital Group; Novartis; Roche$73M-C4 Therapeutics launched from Dana-Farber Cancer Institute on January 7, 2016, with a $73 million Series A financing round led by Cobro Ventures, joined by Cormorant Asset Management, The Kraft Group, EG Capital Group, Roche, Novartis, and angel investors. The company develops novel targeted protein degradation (TPD) therapeutics using proprietary Degronimid technology, pioneered in the Bradner Lab at Dana-Farber since 2010 and described in a 2015 Science paper. Degronimids are chemical adapters that recruit the cell's ubiquitin-proteasome system to degrade disease-causing proteins, particularly undruggable or resistant ones, with initial focus on oncology and potential expansion to other diseases. The financing coincided with appointing Jason Fisherman, M.D., as CEO and board member, leveraging his 30 years in healthcare. C4 also entered a strategic drug discovery collaboration with Roche, where C4 develops TPD therapeutics for specific targets; Roche has an option to advance after preclinical milestones, with the deal potentially worth over $750 million. The company is based in Cambridge, Massachusetts, at Mass Innovation Labs in Kendall Square. C4 positioned itself to advance Degronimid pharmacology for novel medicines targeting proteins resistant to traditional inhibitors.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About C4 Therapeutics

When was C4 Therapeutics founded?C4 Therapeutics was founded in 2015.
Where is C4 Therapeutics headquartered?C4 Therapeutics is headquartered in United States.
How many employees does C4 Therapeutics have?As of today, C4 Therapeutics has over 110 employees.
Who is the CEO of C4 Therapeutics?C4 Therapeutics' CEO is Andrew J. Hirsch.
Is C4 Therapeutics publicly listed?Yes, C4 Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of C4 Therapeutics?C4 Therapeutics trades under CCCC ticker.
When did C4 Therapeutics go public?C4 Therapeutics went public in 2020.
Who are competitors of C4 Therapeutics?C4 Therapeutics main competitors include Prothena Corp., Kyverna Therapeutics, 4D Molecular Therapeutics, Assembly Biosciences, YungShin Global Holding, Synmosa Biopharma, Blau FarmacĂȘutica, CytoDyn, PKU Healthcare, Medigen Vaccine Biologics.
What is the current market cap of C4 Therapeutics?C4 Therapeutics' current market cap is $482M.
What is the current revenue of C4 Therapeutics?C4 Therapeutics' last 12 months revenue is $30M.
What is the current revenue growth of C4 Therapeutics?C4 Therapeutics revenue growth (NTM/LTM) is (29%).
What is the current EV/Revenue multiple of C4 Therapeutics?Current revenue multiple of C4 Therapeutics is 10.0x.
Is C4 Therapeutics profitable?No, C4 Therapeutics is not profitable.
What is the current net income of C4 Therapeutics?C4 Therapeutics' last 12 months net income is ($112M).
How many companies C4 Therapeutics has acquired to date?C4 Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies C4 Therapeutics has invested to date?C4 Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to C4 Therapeutics

Lists including C4 Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial